Critical Outcome Technologies Inc.: COTI-2 Is an Effective Single Agent With Low Toxicity in Multiple Xenograft Models of Human Cancers

LONDON, ONTARIO--(Marketwire - October 15, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) released a summary of animal data today clearly demonstrating that COTI-2 is an effective single agent with low toxicity in six different xenograft models of human cancers.

Generally, attempts to extrapolate from an individual animal model of human cancer to successful human drug trials have been unsuccessful. However, Voskoglou-Nomikos et al (Clinical Cancer Research, 2003) have provided evidence that where an early stage compound produces significant tumor growth inhibition in multiple xenograft models of human cancers there can be a significant correlation with that compound’s Phase 2 clinical success. For that reason COTI-2, a novel AKT inhibitor, was studied in multiple xenograft models of a range of human cancers.

COTI-2, when administered at doses from 3 mg/kg to 125 mg/kg and with dosing schedules ranging from 3 times per week to 5 times per week, significantly inhibited tumor growth in multiple human cancers. These results are summarized in Table 1 below. COTI-2 is an effective single agent since doses as low as 3 mg/kg and a low dose short course of just 5 treatments given over 10 days produced significant tumor growth inhibition in different tumors. In addition, higher doses given up to 5 times per week and for longer periods produced even greater tumor growth inhibitor effects (average TGI equals 63.3% for treatments equals 19 days). COTI-2 also demonstrated low toxicity since doses up to 125 mg/kg administered for up to 36 days were well tolerated by the animals.

 Table 1: A summary of the single agent activity of COTI-2 in six xenograft models of human cancer ---------------------------------------------------------------------------- Cell Cancer Dose Tx TGI line Type Model (mg/kg) Route Days Schedule (%) p Value ---------------------------------------------------------------------------- Small 3 times less than SHP77 Cell Metastatic 3 - 4 IP 38 per 96.2 0.01 Lung week Cancer (SCLC) ---------------------------------------------------------------------------- Up to 5 times less than N417 SCLC Solid 30 IP 29 per 56.8 0.05 week ---------------------------------------------------------------------------- Up to 5 times less than HT29 Colon Solid 10 IP 48 per 54.9 0.05 week ---------------------------------------------------------------------------- 3 times less than U87 Brain Solid Up to 8 IP 10 per 30.0 0.05 week ---------------------------------------------------------------------------- Up to 5 times less than U937 Leukemia Solid 20 IP 19 per 43.8 0.13 week ---------------------------------------------------------------------------- Up to Dose A2780 Ovarian Solid 125 PO 36 range 64.7 0.05 finding ---------------------------------------------------------------------------- IP equals PO equals TGI% equals Tumor Growth Tx equals Intraperitoneal Oral Inhibition Percent Treatment 

“We are very pleased with the significant single agent efficacy and low toxicity of COTI-2 in multiple animal models of human cancers. While traditional cancer chemotherapy is frequently limited by significant toxic side effects, it is drug candidates like COTI-2 that represent a new generation of less toxic drugs with good anti- tumor activity,” said COTI President and CSO, Dr. Wayne Danter. “This data clearly supports the continued development of COTI-2 into human clinical trials. We remain focused on solidifying a licensing agreement with an organization that can assist in advancing COTI-2 forward,” said COTI CEO Mr. Michael Cloutier.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, acute myelogenous leukemia, colorectal cancer and Alzheimer’s disease.

For further information, please visit the website at www.criticaloutcome.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.